you, John, corporate and like our strategies CHF call a to first with quarter Thank and growth. to for earnings This update. Welcome good morning, everyone. to successfully execute XXXX continues of start quarter first growth. review Solutions revenue I'd on our continued morning,
revenue year-over-year year-over-year XXXX, versus quarter representing a $X.X X of QX First was revenue quarters growth. million, XX% double-digit increase consecutive in
Our direct we revenue execution strategy and in of of our investment commercialization result and the sales clinical team. successful is have our U.S. growth a made
results the sales optimistic to quarter and of We about first are pleased continue the with rest year. our be
and April. commercialization focus of pipeline heart our current during robust on surgery strategy the efforts hospital progress patients to Oklahoma, failure. which towards Tulsa, serving make a initiating strengthening to the have addition pediatrics our cardiovascular month eventually hospital we X We Aquadex systems therapy, in the including in of of in continued QX, our systems announced we In
patients volume responding a FlexFlow Aquadex are specialty is System Our of cardiovascular from the for is who that surgeon, excess from be surgery needed the surgery have fluid the significant the of to overload Removing the and because is complications undergone to can assistants. patients form physician's anesthesiologist, ultrafiltration who medical ICU diuretics, discharge not intensivists avoid cardiovascular including opportunity prescribed by cardiovascular pulmonologist, surgery. the to simple growth from in any and treatment expedite
PhD, the before, we calling the hit the a Canada, avoiding As the the in of Surgery mentioned patients weekend, meeting the of prescribed session the and in and weeks, Israel; Dr. This our Margarita Mark with few session use American from was to the cardiothoracic included for video from on Sinai that I thus a In care outcomes Dr. in quality of Health Franklin Beckles, Daniel annual our by specialists from Medstar Oloomi Association website. clinical therapy this and can monitored on System; without Small expect aquapheresis. publish scores. session by in last Mehdi next sponsored Square. a involved Camacho The Newark we physicians attended panel Thoracic improving be potential renowned Toronto, Beth surgery surgeon members any MD recaps Mount where we
is strategy, have include -- preparation the step label which pediatric FDA begun discussions for our patients. now we modify to May for to our scheduled with Regarding XX, FDA, with pre-submission meeting specifically pediatric the in
We with XXXX. currently the and our pediatrics for required oxygenation treat clearance kidney marketing market, treat for of XXX(k) transplant. conditions our surgery, to cardiac therapy patients because the of including extracorporeal pediatrics half are pediatric used Several use therapy, aware the treating organ are in volume are being that products use we disease, anticipate overload, in pediatric We replacement that result of pediatric second many Aquadex fluid hospitals low are to heart system. expanded not patients. membrane blood to Aquadex extracorporeal but children's children's These can for hospitals
Patent spent optimizing to patent of important several important startup at companies, pediatric XXXX. included, use. among Solutions Innerspace since years announced Chief today Nestor joined investment use in pediatric blood circuit including this Craig-Hallum Medtronic, CHF The volume Capital new a sales application the medtech & addition, XX St. years for of group claims, and CEO Most senior the for has addition our in Associates. as also the Jaramillo of experience management customization marketing In past Neuro for Officer. Yesterday, our application recently, Nestor hemodynamics. quarter, and Commercial our Solutions submitted with Jude banking Office we Nestor we than Cherry U.S. Tree He to team. and Medical. Trademark Medical of patient was method X an September more patent industry and Transoma
are the to happy to have someone We forward and with commercial vast our Nestor's team to join many look contributions experience his organization.
continuing strategy systems. we As on health busy QX, and we large move launch in into accounts executing are our to
Given have make our our pipeline, investments to support organization we to decided additional to field the growth. expand strong
therapy to play in an specialists number XX once the and use launched. training proper educating from of account new During important Clinical territories adoption QX, accounts XX our of from and XX. and the specialists role has in X the will to increase sales we therapy clinical increase been on the driving education
associated During article Economics. Heart quarter, $X,XXX analytical announced health probabilistic hospital Patients utilization therapeutics titled for and cost from framework project that either Fluid of outlining important heart interventions. that to and in ultrafiltration decision care System Analysis." in was advantages the follow The therapy. cost higher, literature assessments a treatment with decisions, savings as removal clinical FlexFlow the study first Failure: ultrafiltration the data fluid and diuretic with Aquadex medical versus the a period. the initial journal outcomes the general device system Hospital patients treating with to health the hospital therapy peer-reviewed costs we therapy Results key with XX% or to validated The showed reduced diuretic ultrafiltration, the ultrafiltration overload academic Aquadex from and XX-day data that Diuretics such with Treatment or for a failure to savings Overload Journal were and of economic to A the while of care therapy fluid health with an readmissions, one publication compared in leading costs of "Ultrafiltration cost Medical the in associated It of System, covers examined hospitals Cost over care a
initiating to to FlexFlow treatment technologies Blood are synergies more between providers diagnostic and Aquadex selection, We system the Aquadex strategy physicians informing to to and fluid We effectively health Volume investor patient focused document refine patients. to believe and may physicians Corporation initiate building of several on at discontinue sorry, that identifying -- gross to appropriate We them offering overloaded with we round, QX, which base. I'm researching million. add add management that assist and important dedicated able treat Daxor more to In and will how diagnostic on therapies when which remain multiple manage clinical therapy. therapy clearly BVA-XXX completed evaluate inform with to providing ultrafiltration. care throughout company's the with were solutions the a an therapy, fluid therapy block Daxor's We're how to volume when trial fluid another strengthened investors in manage this to to tools, $XX.X equity our clinical positive a fundamental We and maximize on collaboration Daxor is Analyzer status that results. achieve this help
hospitalists, anticipate primary the ultrafiltration sales worldwide provider position for our of efforts, expanded Given as cardiac accelerated growth and in by market continuing ourselves further surgeons. intensivists the commercialization to therapy we cardiologists,
to outcomes, quality become management CHF international our failed, to with direct four, Our sales our one, is and value execute number treatment turn QX teams; revenue including: strategies improve areas thereby heart as call opportunity walk the and of now faced major when over for clinical investing the clinical improve diuretic applications new management our for customers can fluid market three, will technologies of you have clinical market to challenges continued and/or CHF spearheading management; vision and clinical be our help the footprint; growth, the continues Claudia, continues the to ultrafiltration our through most an manage two, IV awareness system. rehospitalization results fluid Solutions growing life. reduce and growing in care Solutions and investing fluid details. successfully at health rates with current on in fluid growth. of to the therapy-only global forefront financial removal; five, failure, diagnostic developing who XXXX expanding solutions to the importantly, I to with reduce expense in using U.S. our to in increasing introducing distribution patient diuretics target leader of the
and to questions. will Following the comments some call open closing that, we'll provide I
